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A b s t r a c t  
Solid lipid nanopaticles (SLNs) emerged in early 1990s as a next-generation drug delivery system, 
an alternative to traditional colloidal carriers like liposomeÊs, polymeric nanoparticles, emulsions etc. 
Their size range is between 1 to 1000 nm and their biodegradable and inacceptable nature make 
them less toxic and thus better suited to patients. SLNs have got potential applications in 
pharmaceutical field, cosmetics, clinical medicine and other allied sciences. Presently, formulation 
scientists have been focusing on SLNs as colloidal drug carriers for incorporating hydrophilic as well 
as lipophilic drugs. The ability to incorporate drugs into nanocarriers offers a new prototype in drug 
delivery which can be used for drug targeting. They hold great promise for reaching the goal of 
controlled and site specific drug delivery. Furthermore, SLNs have got advantage of being 
introduced in the body by oral, parenteral and topical routes. So the present review attempts to 
enlighten various lipids used in SLNs, manufacturing techniques as well as the potential applications 
through various routes for a variety of disorders. Furthermore, the manuscript also focuses on the 
fate of these lipids (constituents of SLNs) in the body and their way out (i.e. elimination). 
Kewords: Lipid, Nan particles, Biodegradable, Sanitation, Homogenization 
Introduction 
The bioavailability of drugs has been the main issue from decades, 
because about 40% of the commercialized drugs are poorly water 
soluble in nature. These drugs pose difficulties in obtaining 
adequate and reproducible drug absorption from the 
gastrointestinal tract. To overcome these issues, some colloidal 
carriers like nanoemulsions, nanosuspensions, micellar solution 
etc. were introduced previously. However, physical stability, low 
drug loading, drug expulsion on storage, presence of residual 
organic solvents and polymer cytotoxicity are the major drawbacks 
which limit the use of these colloidal carriers. [1] Prof. Rainer Muller 
found out the solution to these drawbacks in solid lipid 
nanoparticles (SLNs). SLNs are small sized lipid nanoparticles 
composed of biocompatible and biodegradable solid lipids. Their 
matrix is compossed of physiological lipids that reduces/decreases 
the danger of acute & chronic toxicity. [2] Despite their small size 
(10-1000nm), they offer high drug loading capacity, larger surface 
area and thus enhanced bioavailability. These characteristics make 
SLNs an interesting drug delivery system. [3]  
 
Figure 1. Solid Lipid Nanoparticle 
SLNs have following advantages [4, 5, 6]. 
 
Enhancement of bioavailability of poorly water soluble drugs. 
High drug loading capacity. 
Site specific delivery of drugs, enhanced drug penetration.  
High physical stability of product.  
Possibility of scaling up.  
Better control over release kinetics of encapsulated compound. 
 
They can be administered through different routes such as oral, 
parenteral, transdermal and ocular. 
The above stated characteristics make SLNs a better alternate over 
colloidal carrier [7]. 
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Various Lipids Used in SLNs 
Fatty acids 
• Stearic acid 
• Palmitic acid 
• Decanoic acid 
• Behenic acid 
Triacylglycerols 
• Trimyristin 
• Tristearin  
• Tricaprin 
• Trilaurin 
• Tripalmitin 
Acylglycerols 
• Glycerol monostearate 
• Glycerol behenate 
• Glycerol Palmitostearate 
Waxes • Cetyl palmitate 
Cyclic complexes • Cyclodextrin 
Hard fat types • Witepsol W 35 • Witepsol H 35 
Others • Cholesterol 
Stearic Acid 
Stearic acid is a hard, white or faintly yellow-colored, somewhat 
glossy, crystalline solid or a white or yellowish white powder. It has 
a slight odor (with an odor threshold of 20 ppm). Chemically its 
name is Octadecanoic acid. Its Molecular formula is C18H36O2 and 
molecular weight is 284.47. [8] 
 
Figure 2. Structure of Stearic Acid 
Soluble in benzene, carbon tetrachloride, chloroform, and ether; 
soluble in ethanol (95%), hexane, and propylene glycol; practically 
insoluble in water. 
Acid value is 195ă212. 
Boiling point is 383ĈC. 
Melting point is 69ă70ĈC. 
Contains practically no water. 
Stearic acid is a stable material; an antioxidant may also be added 
to it. The bulk material should be stored in a well closed container 
in a cool, dry place. 
Palmitic Acid 
Palmitic acid occurs as white crystalline scales with a slight 
characteristic odor and taste. Chemically it is Hexadecanoic acid. 
Its molecular formula is C16H32O2 and molecular weight is 256.42. 
[9] 
 
Figure 3. Structure of Palmitic Acid 
Soluble in ethanol (95%); practically insoluble in water. 
Melting point is 63ă64ĈC. 
Boiling point 351ă352ĈC. 
Acid value is 216ă220. 
The bulk material should be stored in a well-closed container in a 
cool, dry, place. 
Decanoic Acid 
Decanoic acid is a solid compound that belongs to the straight 
chain fatty acids. It is white crystalline solid with a rancid odor. Its 
molecular formula is C22H44O2 and molecular weight is 340.58. [10] 
 
Figure 4 Structure of Decanoic acid 
Melting point is 31.5ĈC 
Practically insoluble in water. 
Soluble in ethanol, ether, chloroform, benzene, carbon disulfide, 
dilute nitric acid 
Behenic Acid 
Behenic acid is white to cream color waxy crystals or powder.  It is 
a carboxylic acid, the saturated fatty acid with formula 
C21H43COOH and molecular weight of 340.59. [11] 
 
Figure 5. Structure of Behenic acid 
Melting point is 79.95ĈC 
Boiling point is 306ĈC 
Slightly soluble in water, ethanol, ethyl ether. 
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Cholesterol occurs as white or faintly yellow, almost odorless, 
pearly leaflets, needles, powder, or granules. On prolonged 
exposure to light and air, cholesterol acquires a yellow to tan color. 
Its molecular formula is C27H46O and molecular weight is 386.67. 
[21] 
 
Figur 13. Structure of Cholesterol 
Melting point is 147-150ĈC. 
Soluble in Acetone, Benzene, Chloroform, Ethanol, Methanol and 
Vegetable oils. 
Practically insoluble in water. 
Various Techniques Used For Preparation of SLNs 
There are different methods for preparation of SLNs: 
High Shear Homogenization Method. 
Hot Homogenization Method. 
Cold Homogenization Method. 
Ultrasonication Method. 
Microemulsion Based Method. 
Solvent Emulsification/ Evaporation Method. 
Solvent Emulsification/ Diffusion Method. 
Double Emulsion Method. 
Supercritical Fluid Method. 
Solvent injection Method. 
Spray Drying Method. 
 
High Shear Homogenization method 
This was the first technique for the preparation of SLNs. It is very 
powerful and reliable technique. With the high pressure of 100-
2000 bar, homogenizer pushes the liquid through narrow gap of 
few microns. The fluid accelerates on a very short distance to very 
high velocity over 1000 km/h. Very high shear stress and cavitation 
forces disrupt the particles down to the submicron range. [21] 
Hot Homogenization Method 
This technique involves temperature higher than melting point of 
lipid. It contains about 5-10 % of lipid content.  A pre-emulsion of 
the drug loaded lipid melt and the aqueous emulsifier phase (same 
temperature) is obtained by high-shear mixing device. High 
temperature results in small size of particle. [22] 
 
Figure 13. Hot homogenization method  
Cold Homogenization 
Cold homogenization technique overcomes disadvantages of hot 
homogenization technique like the temperature-induced drug 
degradation, drug distribution into the aqueous phase during 
homogenization and complexity of the crystallization step of the 
nanoemulsion leading to several modifications. Solubilization or 
dispersion of the drug in the melted lipid is same as hot 
homogenization technique. Then it is solidified with dry ice or liquid 
nitrogen. Size of solid is reduced by using mortar mill or ball mill to 
50-100 microns. These microparticles are dispersed in aqueous 
phase as pre-emulsion. Then this pre-emulsion is homogenized at 
high speed below room temperature to obtain SLNs. [23] 
 
 
Figure 14. Cold homogenization method 
Ultrasonication or High Speed Homogenization Method 
Ultrasonication or High Speed Homogenization is another 
technique to prepare SLNs with ease. It is simple in comparison to 
hot and cold homogenization technique, because equipment used 
is very common. Firstly, the drug is added to melted lipid. Then 
heated aqueous phase (at same temperature) is added to this 
melted lipid and emulsified by probe sonicator. This pre-emulsion is 
ultrasonicated using probe sonicator. Keeping at least 5ĈC above 
melting point of lipid, it prevents recrystalization. Obtained SLNs 
Singh et al. International Journal of Drug Delivery 8 (3) 66-76 [2016] 
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are filtered through 0.45øm membrane to remove impurities and 
stored at 4ĈC. [24] 
 
 
 Figure 15. Ultrasonication or High speed homogenization method 
Microemulsion based method 
Dilution of microemulsions based method contains microemulsions 
having two-phase systems composed of an inner and outer phase 
(e.g. o/w microemulsions). In this technique, mixture of a low 
melting fatty acid (e.g. stearic acid), an emulsifier (e.g. polysorbate 
20), co-emulsifiers (e.g. butanol) and water is prepared by stirring 
at temperature of 65-70ĈC until it becomes optically transparent. 
This hot microemulsion is dispersed in cold water (2-3ĈC) under 
stirring. The dilution process is critically determined by the 
composition of the micro emulsion. After dilution process, 
dispersion medium is washed by ultrafiltration system. [25]  
 
 
Figure 16. Microemulsion based method 
Solvent emulsification-evaporation method 
In this method, the lipid and hydrophobic drug is dissolved in a 
water immiscible organic solvent like cyclohexane, 
dichloromethane, toluene, chloroform, etc. Then emulsification is 
done in an aqueous phase by using high speed homogenizer. The 
micro fluidizer is used for coarse emulsion, which improves the 
efficiency of fine emulsification. Then the organic solvent is 
evaporated by rotary evaporator by maintaining its temperature at 
room temperature. SLNs of size 25nm can be obtained by using 
this method. [26] 
 
 
Figure 17. Solvent emulsification-evaporation method 
Solvent emulsification- diffusion method 
In solvent emulsification- diffusion method, partially water miscible 
solvents like benzyl alcohol, ethyl acetate, methyl acetate etc. are 
used. Solvent and water are saturated until they gain 
thermodynamic equilibrium. Saturation step requires heating if lipid 
requires heat to solubilisation. Drug and lipid is added to this 
saturated solution of solvent and water using mechanical stirrer. 
This will form o/w emulsion. Water in ratio of 1:5 to 1:10 is added 
for diffusion to continuous phase to form aggregation of lipid in 
nanoparticles. Temperature is maintained to room temperature or 
at temperature at which lipid is dissolved. After lyophilization or 
vaccume distillation, SLNs are obtained. [27] 
 
 
Figure 18. Solvent Emulsification- Diffusion method 
Double emulsion method 
In this technique, the hydrophilic drug is dissolved in aqueous 
solution and emulsified in melted lipid to form primary emulsion. 
The stabilizers like gelatine or poloxamer 407 are added in this 
primary emulsion to stabilize it. On the other side, the aqueous 
phase containing hydrophilic emulsifier by adding PVA is prepared 
Singh et al. International Journal of Drug Delivery 8 (3) 66-76 [2016] 
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and primary emulsion is added to it. This double emulsion is stirred 
and is isolated by filtration. [28] 
 
 
Figure 19. Double emulsion method 
Supercritical Fluid Method 
The supercritical fluid technology is a novel technique, which 
eliminates solvent processing steps. In this technique, water-
insoluble drugs are combined with lipids and lipid nanosuspension 
is formed. The continuous supercritical fluid extraction of emulsions 
method is used for precipitation of solid lipid nanoparticles. The 
rapid expansion of supercritical carbon dioxide solutions (RESS 
method) produces SLNs. [29] 
 
Solvent injection technique 
This is the technique which is based on lipid precipitation from the 
dissolved lipid in solution. Then the solid lipid is dissolved in a 
water-miscible solvent like ethanol, acetone, isopropanol or their 
mixture. Then this organic solvent mixture is slowly injected through 
an injection needle in to stirred aqueous phase with surfactant. The 
dispersion so formed is sonicated for 12 minutes to obtain SLNs. 
[30]  
 
 
Figure 20. Solvent injection method 
Spray Drying Method 
Spray-drying is a process for preparing SLNs which converts a 
liquid feed to a dried particulate form. The feed is a solution, but it 
can also be a coarse or fine suspension or a colloidal dispersion 
(e.g., emulsions, liposomes, etc.). Firstly, this feed is atomised 
through various techniques (centrifugal, pneumatic, ultrasonic and 
electrostatic atomisation) to a spray form, which is put immediately 
into thermal contact with a hot gas, resulting in the rapid 
evaporation of the solvent to form dried solid particles. [31] The 
dried particles are then separated from the gas by means of a 
cyclone, an electrostatic precipitator or a bag filter.  
Table 1. Various lipids used with different techniques for formulation of SLNs 
Lipid Drug Technique Reference 
Glyceryl 
monostearate 
Haloperidol Emulsificationădiffusion technique Yasir et al. 2014. [32]
Vinpocetine Ultrasonic solvent emulsification Luo et al. 2006. [33]
Efavirenz Hot homogenization method Gaur et. al. 2014. [34]
Dibenzoyl peroxide, Erythromycin 
base, and Triamcinolone acetonide 
High shear hot homogenization Gardouh et.al 2013. [35] 
Trimyristin Letrozole Hot homogenization -ultrasonication Nerella et al. 2014. [36]
Tristearin 
Dithranol Solvent emulsification evaporation Khan et. al. 2012. [37]
Clozapine Modified hot homogenization Venkateswarlu et. al. 2004. [38]
Glyceryl behenate Valsartan Solvent injection method Parmar et. al. 2011 [39]
Cetyl palmitate Rifampin Microemulsion-based method Aboutaleb et. al. 2012. [40]
Stearic acid Carbamazepine Rapid Expansion of Supercritical Solution (Supercritical Fluid Method) Akbari et. al. 2014. [41] 
Tripalmitin  
Paclitaxel  Microemulsion  based method Cavalli et. al. 2000. [42]
Catalase Double Emulsion Method Ce Qi et. al. 2011. [43]
Palmitic acid Moxifloxacin Microemulsion  based method Silpa et. al. 2012. [44]
Cholesterol Salbutamol sulfate Spray Drying Method Daman et. al. 2014. [45]
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Applications of SLNs through various routes 
Oral administration 
For the drugs having low bioavailability through the oral route, 
SLNs are very useful approach for their delivery. These systems 
have controlled release behavior and bypass the gastric and 
intestinal degradation of the drug. [46] It provides transport of drug 
though GIT mucosa. The adhesive property of SLNs also reported 
to increase bioavailability and reduce or minimize erratic 
absorption. [47] Their firmness upon contact with gastrointestinal 
(GI) fluids since they are poised of biodegradable materials and 
having particle size in nanorange maximizes the surface area for 
enzymatic degradation. For the oral administration, lyophilized 
SLNs, powder can be placed into capsules, compressed into 
tablets or integrated into pellets.  
Parenteral administration 
SLNs consist of physiologically well-tolerated ingredients and have 
fine storage capabilities after lyophilization, which are very 
appropriate for systemic delivery. With parenteral administration, 
the approach of targeted gene therapy in the treatment of cancer 
can be executed by using cationic SLNs, which attach to genes via 
electrostatic interactions. [48] The plasma half life and steadiness 
of the SLNs can be increased by coating SLNs with polymers like 
PEG, which will reduce phagocytic uptake and increase 
bioavailability. [49] 
Rectal administration  
Rectal route is used for pediatric patients due to easy application. 
In some circumstances, when faster pharmacological action is 
needed, rectal route is preferred. With similar dose, rectal route 
reported superior plasma levels and therapeutic effectiveness than 
oral or intramuscular route.  [50] 
Nasal administration 
Nasal route gives fasten absorption and rapid onset action of drug. 
It avoids degradation of drug by GIT fluids and poor transport 
across epithelial cell layers. Nasal route can also be used for 
targeting the brain. [51] 
Respiratory delivery  
Respiratory route for SLNs is a novel approach for delivery of 
drugs. This route through lungs avoids first pass effects by offering 
a high surface area for drug absorption. Solid lipid particles have 
effective carrying capacity for anti-tubercular drugs, anti-asthmatic 
drugs and anticancer drugs, enhancing their bioavailability and 
reducing the dosing frequency for better management of pulmonary 
action. [52]  
Transdermal route 
SLNs are having lipid contents, which are having great penetrating 
power across the skin. They are well suitable for use on inflamed or 
damaged skin because they are based on non-toxic and non-irritant 
lipids. [53] 
Ocular route 
Eyes have multiple barriers resisting penetration of drugs. Ocular 
delivery is considered as the most difficult thing to achieve. Drug 
absorption and bioavailability is poor by ocular route. To overcome 
these challenges, SLNs having muco-adhesive properties improve 
interaction with eye mucosa and prolong corneal resisting time of 
drug. It gives improved bioavailability and targeting effect. [54]   
Fate of Lipids/Excretion of Lipids/Degradation 
Mechanism of Lipids in-vivo 
The solid lipids in SLNs can be degraded by pancreatic lipases in 
the GI tracts when administrated orally. There are some in-vitro 
models which show process of enzymatic degradation. [55] There 
is some relation of degradation of lipid with the length of fatty acid 
chains. Degradation will be slow if the chains will be longer. The 
influence of surfactants in the formulation can be either degradation 
accelerating (e.g. sodium cholate) or hindering, degradation show 
down effect due to steric stabilization (e.g. Poloxamer 407). [56] 
Fast degradation was noticed when the size of SLNs were in renge 
of 180-300 nm, and size having 800 nm showed slow degradation. 
[57] SLNs which were having low crystallinity matrix (Dynasan 114 
and 116, sodium cholate) show faster degradation than higher 
crystalline particles (all SLN with Poloxamer 407). [58] Little 
information is available till now for the fate of intravenously 
administered SLNs. Although the distribution of SLNs had been 
investigated by monitoring the drug level or the tracing elements 
such as fluorescent probes or nuclear substances, we know little 
about the metabolism and excretion of either the SLNs vehicle itself 
or the lipids comprising the vehicle. Most of the SLNs accumulate 
in the liver, spleen, or lungs, degraded at the place, when 
intravenously administered. The fatty alcohol dehydrogenase is 
present in the liver, which degrade fatty alcohol-based SLNs (e.g. 
cetyl or stearyl alcohol). In-vitro incubation of cetyl or stearyl 
alcohol-based SLNs with alcohol dehydrogenase enzymes showed 
80-90% degradation after 15-24 h, which suggested similar 
degradation mechanisms of SLNs in-vivo. The release of drug 
molecule and disruption of SLNs can be increased by enzymatic 
degradation. [59] It is revealed by in-vivo studies that an ocular 
SLN system have increased residence time on the ocular surface 
and conjunctival sac as compared to an aqueous eye drops, which 
leads to the sustained release of the drug. SLNs have small particle 
size due to which it has increased adhesive ability and decreased 
clearance of the nasolachrymal duct. [60] The thiolated SLNs have 
found to increase the mucoadhesive properties and slowed down 
the rate of elimination from ocular surface. [61] SLNs also have 
their role in pulmonary delivery. SLNs of larger sizes get deposited 
in the throat and the smaller sizes get exhaled without any 
deposition in the end of bronchus. [62] SLNs that reach the 
pulmonary alveoli get eliminated by clearance route other than 
Singh et al. International Journal of Drug Delivery 8 (3) 66-76 [2016] 
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respiration and also through the mucociliary escalator; the 
clearance shows the rapid initial elimination phase. [63] SLNs also 
work to target a lymphatic system because after few minutes, 
inhaled particles begin to translocate to regional lymph nodes. [64] 
Conclusion 
The selection of appropriate drug carrier, possessing non-toxicity 
and neutrality to our body system and, crucially, compatible with 
the active substance, is a very smart task, not an easy one. In 
recent years the solid lipid nanoparticles have proved to be the 
ideal solution to this problem and an alternative to traditional 
colloidal and vesicular systems. The SLN are exciting carrier 
systems for encapsulating bioactive substances with considerable 
potential for application. Along with a number of advantages we 
discussed earlier, SLNs have certain grey areas also which include 
low drug loading capacity, product stability aspect which is 
associated with the possibility of gelation, particle size increase 
(agglomeration) and drug releasing characteristics. So it can be 
concluded that the future holds great promise for its systematic 
investigation and exploitation. 
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